Fundraising Fox
iTolerance
Miami, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into iTolerance
Sign up to see every warm intro you have to iTolerance
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iTolerance team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iTolerance develops the SA-FasL microgel (iTOL-100) immunomodulatory technology aimed at enabling cell and tissue transplantation, such as insulin-producing islet cells for diabetes, without continuous anti-rejection drugs. The company operates in regenerative medicine and transplantation immunology.
Founders & leadership
AJ
Anthony JapourChief Executive Officer2021–2026Anthony Japour holds an MD and has spent over 30 years in physician-executive and biotech pharmaceutical leadership roles, including clinical development, FDA strategy, and global commercial launches; he currently serves as CEO of iTolerance, developing immunomodulatory technologies for transplantation and regenerative medicine.
CR
Camillo RicordiChief Scientist
ES
Esma S. YolcuChief Technical Scientist
AJ
Anthony Japour In remembranceChief Executive Officer2021–2026
CG
Cameron GrayChief Executive Officer, Founder and Director
PA
Peter A. KienerNamed on SEC filing
Investors · 1
__Twitter.png)
Reported raises · per SEC filings
Form D private placements$17.2M disclosed across 1 round · 2021
▶$17.2MraisedFeb 2022 · 144 investors · BiotechnologyRule 506(b)
▶$17.2MraisedFeb 2022 · 144 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cameron GrayDirector
- Anthony JapourExecutive Officer, Director
- Peter A. KienerDirector
- Offering amount
- $20M
- Amount sold
- $17.2M
- Sales commissions
- $1.5M
- Placement agents
- National Securities Corporation
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as iTolerance.
Frequently asked questions
- What does iTolerance do?
- iTolerance develops the SA-FasL microgel (iTOL-100) immunomodulatory technology aimed at enabling cell and tissue transplantation, such as insulin-producing islet cells for diabetes, without continuous anti-rejection drugs. The company operates in regenerative medicine and transplantation immunology.
- Who are iTolerance's investors?
- iTolerance's investors include Gaingels.
- How much funding has iTolerance raised?
- iTolerance has disclosed $17.2M raised across 1 round.
- Where is iTolerance headquartered?
- iTolerance is headquartered in Miami, US.